David A Walker
Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials
Walker, David A; Meijer, Lisethe; Coyle, Beth; Halsey, Christina
Authors
Lisethe Meijer
Professor BETH COYLE BETH.COYLE@NOTTINGHAM.AC.UK
PROFESSOR OF BRAIN TUMOUR MICROENVIRONMENT
Christina Halsey
Abstract
Leptomeningeal malignancy complicates childhood cancers, including leukaemias, brain tumours, and solid tumours. In leukaemia, such malignancy is thought to invade leptomeninges via the vascular route. In brain tumours, dissemination from the primary tumour, before or after surgery, via CSF pathways is assumed; however, evidence exists to support the vascular route of dissemination. Success in treating leptomeningeal malignancy represents a rate-limiting step to cure, which has been successfully overcome in leukaemia with intensified systemic therapy combined with intra-CSF therapy, which replaced cranial radiotherapy for many patients. This de-escalated CNS-directed therapy is still associated with some neurotoxicity. The balanced benefit justifies exploration of ways to further de-escalate CNS-directed therapy. For primary brain tumours, standard therapy is craniospinal radiotherapy, but attendant risk of acute and delayed brain injury and endocrine deficiencies compounds post-radiation impairment of spinal growth. Alternative ways of treating leptomeninges by intensifying drug therapy delivered to CSF are being investigated—preliminary evidence suggests improved outcomes. This Review seeks to describe methods of intra-CSF drug delivery and drugs in use, and consider how the technique could be modified and additional drugs might be selected for this route of administration.
Citation
Walker, D. A., Meijer, L., Coyle, B., & Halsey, C. (2020). Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials. Lancet Child and Adolescent Health, 4(3), 242-250. https://doi.org/10.1016/s2352-4642%2819%2930333-5
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 10, 2020 |
Online Publication Date | Jan 17, 2020 |
Publication Date | 2020-03 |
Deposit Date | Mar 6, 2020 |
Publicly Available Date | Jul 18, 2020 |
Journal | The Lancet Child & Adolescent Health |
Electronic ISSN | 2352-4642 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 4 |
Issue | 3 |
Pages | 242-250 |
DOI | https://doi.org/10.1016/s2352-4642%2819%2930333-5 |
Public URL | https://nottingham-repository.worktribe.com/output/4097345 |
Publisher URL | https://www.sciencedirect.com/science/article/abs/pii/S2352464219303335 |
Additional Information | This article is maintained by: Elsevier; Article Title: Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials; Journal Title: The Lancet Child & Adolescent Health; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S2352-4642(19)30333-5; Content Type: article; Copyright: © 2020 Elsevier Ltd. All rights reserved. |
Files
LM Disease
(486 Kb)
PDF
LM disease
(154 Kb)
PDF
Licence
No License Set (All rights reserved)
Publisher Licence URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
LM Disease
(157 Kb)
PDF
Licence
No License Set (All rights reserved)
Publisher Licence URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
You might also like
Recommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies
(2023)
Journal Article
Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature
(2023)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search